Randomised, double-blind, placebo-controlled, parallel-group design, multi-centre, dose-escalation phase III trial to investigate the efficacy, safety, and tolerability of Naloxone HCl PR tablets administered in a dose range of 3 mg to 24 mg twice daily in patients with opioid induced constipation
Latest Information Update: 23 Feb 2018
At a glance
- Drugs Naloxone (Primary)
- Indications Constipation
- Focus Therapeutic Use
- 27 Dec 2012 New trial record